


CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound represented by formula I:



wherein


R¹ is selected from the group consisting of H, halogen, (C₁₋₄)alkyl, O(C₁₋₆)alkyl, and haloalkyl;

R₂ is H or (C₁₋₄)alkyl;





R³ is H or (C₁₋₄)alkyl;

R⁴ is (C₁₋₄)alkyl, (C₁₋₄)alkyl(C₃₋₇)cycloalkyl, or (C₃₋₇)cycloalkyl; and

Q is a fused phenyl-5 or 6-membered saturated heterocycle having one to two heteroatoms selected from O and N, said **Q** is selected from the group consisting of:

a)  wherein one of **E** and **G** is C(O) and the other is **NR⁵** wherein **R⁵** is selected from the group consisting of H, hydroxy and (C₁₋₄)alkyl unsubstituted or substituted with pyridinylmethyl, (pyridinyl-N-oxide)methyl or C(O)OR⁶ wherein **R⁶**

is H or (C₁₋₄)alkyl; and each **R**⁷ is independently H, Me or Et; or




or a pharmaceutically acceptable salt, ~~or prodrug~~ thereof.

Claim 2 (currently amended): The compound according to claim 1, wherein **R**¹ is



selected from: H, Cl, F, (C₁₋₄)alkyl and CF₃; **R**² and **R**³ is each independently H or Me; **R**⁴ is ethyl or cyclopropyl; and

Q is selected from:



wherein **R**⁵ is H, hydroxy, CH₃ or (4-


pyridinyl)methyl;



wherein **R**¹² is H, Me

or CH₂C(O)OH,

or **Q** is further selected from:




wherein **R**¹⁴ is H, Me or

CH₂C(O)OH and each **R**¹⁸ is independently H or Me; More preferably, **R**¹⁴ is H or

CH₂C(O)OH and each **R**¹⁸ is H,


or **Q** is further selected from:




wherein R^{15} is H, Me or $CH_2C(O)OH$ and

R^{16} is H, Me or $CH_2C(O)OH$. More preferably, R^{15} is H or CH_3 and R^{16} is H, CH_3 or $CH_2C(O)OH$.

Claim 3 (original): The compound according to claim 2, wherein R^1 is H, Cl, F or Me; R^2 is H; R^3 is Me; R^4 is ethyl; and Q is selected from:




wherein R^5 is H, hydroxy or (4-pyridinyl)methyl;



wherein R^{14} is H or

$CH_2C(O)OH$ and each R^{18} is H,


or




wherein R^{15} is H or CH_3 and R^{16} is H, CH_3

or $CH_2C(O)OH$.

Claim 4 (original): The compound according to claim 3, wherein **Q** is selected from:



Claim 5 (original): The compound according to claim 4, wherein **R**¹ is H, **R**² is H, **R**³ is Me, **R**⁴ is ethyl and **Q** is selected from:



Claim 6 (currently amended): A pharmaceutical composition for the treatment or prevention of HIV infection, comprising a compound of formula I according to claim 1, or a pharmaceutically acceptable salt, or prodrug thereof, and a pharmaceutically acceptable carrier.

Claim 7 (currently amended): A method for the treatment or prevention of HIV infection, comprising administering to a patient an HIV inhibiting amount of a compound of formula I according to claim 1, or a pharmaceutically acceptable salt, or

prodrug thereof.

Claim 8 (currently amended): A method for the treatment or prevention of HIV infection, comprising administering to a patient an HIV inhibiting amount of a pharmaceutical composition, according to claim 6.


Claim 9 (cancelled)

Claim 10 (currently amended): A method for preventing perinatal transmission of ~~HIV-1~~ HIV-1 from mother to baby, comprising administering a compound of formula I according to claim 1, to the mother before giving birth.

Claim 11 (cancelled)

Claim 12 (original): A process for producing a compound of formula I according to claim 1, comprising steps of:





- coupling a compound of formula 2:



wherein R^1 , R^2 , R^3 and R^4 are as defined in claim 1;

with a phenolic derivative selected from:

a)
wherein one of **E** and **G** is C(O) and the other is NR^{5A}
wherein R^{5A} is a N-protecting group, hydroxy or (C_{1-4}) alkyl unsubstituted or substituted with pyridylmethyl, (pyridinyl-N-oxide) methyl or $C(O)OR^{6A}$ wherein R^{6A} is a carboxy protecting group or (C_{1-4}) alkyl; and each R^7 is independently H, Me or Et.



- removing any protective groups in a mixture of aqueous base or aqueous acid in a co-solvent, to obtain the corresponding compound of formula I.

Claim 13 (cancelled)

Application No. 10/662,856
Amendment dated May 8, 2006
Reply to Office action of November 21, 2005

Claim 14 (cancelled)

Claim 15 (cancelled)